Johnson & Johnson’s vaccine candidate protected against infection by SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. — Photo courtesy of the company Johnson & Johnson on July 30 announced that its lead vaccine candidate protected against infection by SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study. Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium. Paul Stoffels, M.D., vice chairman of the executive committee and Chief Scientific Officer for Johnson & Johnson, said: “We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose. The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention… Read full this story
- U.S. Fed's Beige Book reports negative impact of COVID-19 on economy
- Coronavirus COVID-19 has begun spreading in Australia. So, what happens now?
- Transport industry discusses solutions to reduce damages by Covid-19
- ELEVEN DAYS after floods devastated the regions that voted him into power, Boris Johnson sits dry at home in Downing Street with Austrian Chancellor... so when WILL he visit?
- No need to panic, Kejriwal tells residents amid COVID-19 fear
- COVID-19 brings turmoil to real estate market of Vietnam
- Boris Johnson rejects Brussels’ trade demands in just four hours after EU sets out string of conditions for Britain
- Dwayne Johnson and Jason Statham Partner Up as
- Chinese scientists claim they have developed an oral vaccine to beat coronavirus using baker's yeast
- The Trump administration's ludicrous approach to coronavirus vaccine
Johnson & Johnson COVID-19 vaccine candidate demonstrates protection in pre-clinical studies have 342 words, post on bizhub.vn at August 4, 2020. This is cached page on Talk Vietnam. If you want remove this page, please contact us.